Stem Cell News

BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.

As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.

Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.

Aruna Bio Announces FDA Clearance of IND for Lead Program AB126, Enabling the First Exosome to Enter in Human Clinical Trials for a Neurological Indication

April 6, 2024 By Cade Hildreth, Founder & President Leave a Comment

-Phase 1b/2a clinical trial in acute ischemic stroke expected to initiate in 1H 2024-

-Marks the first IND for Aruna’s platform with plans to expand AB126, an unmodified exosome derived from proprietary neural stem cells, to other neurological indications including amyotrophic lateral sclerosis-

-Proprietary in-house GMP production capabilities enable scalable, reproducible production of clinical-grade exosomes with high purity and uniformity; analytical methods and well-characterized assays established to ensure therapeutic consistency-

[Read more…]

Cryo-Cell to Spin-off Celle Corp., Its Subsidiary Holding Assets Not Directly Associated with Recurring Revenue from Biopreservation

April 2, 2024 By Cade Hildreth, Founder & President Leave a Comment

Celle Corp. holds certain assets of Cryo-Cell not directly associated with its recurring revenue derived from privately banked cord blood specimens.

OLDSMAR, Fla.–Cryo-Cell International, Inc. (NYSE American LLC: CCEL), the world’s first private cord blood bank to separate and store stem cells in 1992, announced that its Board of Directors has authorized the spin-off of its newly formed subsidiary, Celle Corp., to the Cryo-Cell shareholders and to explore all strategic alternatives for Cryo-Cell (post spin-off) to maximize shareholder value, including, but not limited to, equity and/or debt financings and/or the possible sale or merger of the company. There is no assurance that such a transaction will take place. [Read more…]

Defined Bioscience Introduces Ready-CEPT™: A New Cell Viability Enhancer

April 1, 2024 By Cade Hildreth, Founder & President Leave a Comment

Defined Bioscience is pleased to announce the launch of Ready-CEPT™ 1000X, a new product designed to improve stem cell survival, growth, and health during critical processes such as routine passaging, cryopreservation, and freeze-thaw recovery.

San Diego, CA, April 1, 2024 – Defined Bioscience is pleased to announce the launch of Ready-CEPT™ 1000X, a new product designed to improve stem cell survival, growth, and health during critical processes such as routine passaging, cryopreservation, and freeze-thaw recovery. This product introduces a reliable solution for researchers in stem cell research and biotechnology, focusing on enhancing cell viability. [Read more…]

Stem Cells Surpass Landmark Milestone of 500K Scientific Publications

March 30, 2024 By Cade Hildreth, Founder & President 1 Comment

Wow, a tremendous achievement has been accomplished by the stem cell community. We have officially surpassed 500,000 publications about stem cells on PubMed.gov! PubMed is a service of the U.S. National Library of Medicine and NIH that comprises more than 27 million citations for biomedical literature. It is the largest and most comprehensive global database that exists for scientific publications anywhere in the world. [Read more…]

Endonovo Therapeutics Files Patent Application for Cell Therapy Created Using Cord Blood and Tissue Derived Cells

March 23, 2024 By Cade Hildreth, Founder & President Leave a Comment

Therapeutic Represents the First Product to Be Created Using the Company’s Cytotronic™ Platform to Expand and Enhance the Therapeutic Properties of Stem Cells

LOS ANGELES, CA– Oct 27, 2015 – Endonovo Therapeutics, Inc. (OTCQB: ENDV), an innovative biotechnology company developing bioelectronics-based products and therapies for regenerative medicine, announced that it has filed a patent application with the United States Patent and Trademark Office (USPTO) on a perivascular cell mixture created using its proprietary Cytotronics™ Platform that would allow for the wide spread use of cord blood in the treatment of malignant and non-malignant hematological disorders. [Read more…]